Drugmaker Pfizer and its German partner BioNTech said today (November 18, 2020) they would be submitting their coronavirus vaccine candidate for regulatory approval "within days" after their final analysis revealed the treatment was 95% effective with no major side effects, according to the NY Daily News website.
The drug's phase 3 trial -- now complete -- confirmed the vaccine was consistently effective across "age, gender, race, and ethnicity demographics," the company said in a statement.
Of the 41,135 adult volunteers who have received the treatment so far, none has exhibited any serious side effects.
However, nearly 4% of volunteers said they'd been experiencing fatigue, while another 2% reported headaches after the second shot.
No comments:
Post a Comment